Therapeutic Targets in Inflammatory Bowel Disease: Are We Getting the Point Across?

Affiliations

¹ IBD Center, Division of Gastroenterology, Virginia Tech Carilion School of Medicine, Roanoke, Virginia and Department of Clinical and Experimental, Medical Science University of Udine School of Medicine, Udine, Italy.

Comment

Dario Sorrentino. Gastroenterology. 2018 Oct.

. 2018 Oct;155(4):1277-1278.

doi: 10.1053/j.gastro.2018.06.084. Epub 2018 Sep 14.

¹ IBD Center, Division of Gastroenterology, Virginia Tech Carilion School of Medicine, Roanoke, Virginia and Department of Clinical and Experimental, Medical Science University of Udine School of Medicine, Udine, Italy.

No abstract available

Comment in

Reply.
D'Haens G, Vermeire S, Laharie D. D'Haens G, et al. Gastroenterology. 2018 Oct;155(4):1278-1279. doi: 10.1053/j.gastro.2018.09.027. Epub 2018 Sep 17. Gastroenterology. 2018. PMID: 30236558 No abstract available.

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Gils A, Chevret S, Laharie D; GETAID. D'Haens G, et al. Gastroenterology. 2018 Apr;154(5):1343-1351.e1. doi: 10.1053/j.gastro.2018.01.004. Epub 2018 Jan 6. Gastroenterology. 2018. PMID: 29317275 Clinical Trial.